Genetics
CETP Taq1B is linked to glycated hemoglobin levels in hyperlipidemic patients with diabetes, a link modulated by an LIPG variant (Can J Diabetes 2016)
Original title: Association of the CETP Taq1B and LIPG Thr111Ile Polymorphisms with Glycated Hemoglobin and Blood Lipids in Newly Diagnosed Hyperlipidemic Patients
This study examined the association of CETP Taq1B (rs708272) and endothelial lipase LIPG Thr111Ile (rs2000813) polymorphisms with glycated hemoglobin (A1C), blood lipid levels, and type 2 diabetes risk in 175 hyperlipidemic patients from northern Greece, categorized by presence or absence of type 2 diabetes. The CETP Taq1B polymorphism was associated with both HDL-cholesterol and A1C levels, but the associations depended on diabetes status: the A1C association was significant only in patients with type 2 diabetes (p=0.005), while the HDL-cholesterol association occurred only in patients without diabetes (p less than 0.001). LIPG Thr111Ile did not independently affect HDL-cholesterol or A1C but modulated their association with CETP Taq1B, with LIPG 111IleIle homozygotes tending toward higher frequency in diabetic hyperlipidemic patients (p=0.056). The authors conclude CETP Taq1B is associated with A1C levels in addition to its known HDL-cholesterol association, modified by diabetes status and LIPG genotype.
Original abstract
Objective: To examine the association of 2 common polymorphisms in high-density lipoprotein (HDL)-related genes, namely, cholesterol ester transfer protein CETP Taq1B (rs708272) and endothelial lipase LIPG Thr111Ile (rs2000813), with glycated hemoglobin (A1C), blood lipid levels and the risk for type 2 diabetes in a group of hyperlipidemic patients from northern Greece.
Methods: We categorized 175 patients with hyperlipidemia into 2 subgroups according to the presence or absence of type 2 diabetes, defined as a recent diagnosis, A1C >6.5% and/or fasting glucose >126 mg/dL. Genotypes for the 2 polymorphisms studied were determined by polymerase chain reaction-restriction fragment length polymorphism. Both polymorphisms were analyzed by multivariate and univariate analyses of baseline A1C levels and plasma lipids. The genotype and allele frequencies of the 2 subgroups were compared.
Results: The CETP Taq1B polymorphism was associated with HDL-cholesterol (HDL-C) and A1C levels, but this association was affected by type 2 diabetes; the association with A1C levels was significant only in type 2 diabetes (p=0.005), whereas the association with HDL-C occurred only in the subgroup without type 2 diabetes (p<0.001). LIPG Thr111Ile did not affect plasma HDL-C or A1C levels independently but appeared to modulate their association with CETP Taq1B, and LIPG 111IleIle homozygotes tended to be present at a higher frequency in the hyperlipidemic patients with type 2 diabetes compared to the hyperlipidemic patients without type 2 diabetes (p=0.056).
Conclusions: In hyperlipidemic patients, apart from its known association with HDL-C, CETP Taq1B is also associated with A1C levels, and both associations are modified by type 2 diabetes and LIPG Thr111Ile.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.